Linde (LIN), a leader in the bio-tech market, continues to demonstrate strong growth. This upswing has been reflected in stock movement, with shares crossing the 200-day moving average, pushing the target price higher on multiple occasions. Institutions like the National Bank of Canada and Charles Schwab Investment Management have significantly changed their positions on LIN, with notable sales and purchases. Despite fluctuations and a tug of war between price hikes and cuts, the company has consistently overcome market fluctuations, beating both earnings per share (EPS) and revenue estimates for Q1 2024.
Insiders are also active, with CEO Sanjiv Lamba selling a significant portion of shares. Meanwhile, investor interest remains strong, demonstrated by Welch & Forbes LLC and Metis Global Partners LLC buying thousands of shares. Skepticism around LIN's future performance seems limited. The company is heralded as a top pick for hydrogen stocks, demonstrating excellent pricing power. Despite a few downgrades and price target cuts, the analysts at Mizuho and BMO Capital Markets indicates continuing investor belief in Linde's potential.
Linde Stocks LIN News Analytics from Sat, 07 Oct 2023 07:00:00 GMT to Thu, 09 May 2024 19:06:57 GMT - Rating 8 - Innovation 7 - Information 7 - Rumor 6